Non-AIDS-related lymphomatous meningitis: combined modality therapy.
Twenty-two patients (age range, 38 to 69 years; median, 60 years) with lymphomatous meningitis due to metastatic non-AIDS-related non-Hodgkin's lymphoma were treated. Cytologic responses were seen in 16 patients (73%) to first-line chemotherapy, 7 patients (58%) to second-line chemotherapy, and 2 patients (40%) to third-line chemotherapy. Median survival was 10 months (range, 3 to 24 months).
Chamberlain
M C
MC
University of California, San Diego, Department of Neurosciences, La Jolla 92093-8421, USA.
Kormanik
P A
PA
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000188:drug therapy*; D008581:Meningitis / Q000209:etiology*; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011446:Prospective Studies; D016019:Survival Analysis; D013852:Thiotepa / Q000008:administration & dosage; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D003561:Cytarabine; D013852:Thiotepa; D008727:Methotrexate